跳至主要内容
临床试验/NCT07121387
NCT07121387已完成不适用

A Real-World Retrospective Cohort Analysis of SMARCA4-Deficient Advanced Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, China1 个研究点 分布在 1 个国家目标入组 221 人开始时间: 2020年1月1日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
221
试验地点
1
主要终点
Progression-free survival (PFS)

研究概览

简要总结

This is a single-center retrospective analysis to explore the clinical characteristics, therapeutic efficacy, and tumor immune microenvironment of SMARCA4-deficient advanced non-small-cell lung cancer (NSCLC).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosed with stage III-IV NSCLC according to the American Joint Committee on Cancer staging criteria (7th edition);
  • Lesions are measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
  • Receiving first-line immunotherapy or chemotherapy as anti-tumor treatment.

排除标准

  • SMARCA4 gene test was not performed;
  • Not receive treatment;
  • Lost to follow-up after one treatment cycle.

结局指标

主要结局

Progression-free survival (PFS)

时间窗: 5 years

Time from the beginning of first-line therapy to the first progression (PD) in patients with lung cancer

次要结局

  • Overall survival (OS)(5 years)
  • Objective Response Rate (ORR)(5 years)
  • Disease control rate (DCR)(5 years)

研究者

发起方
Shanghai Pulmonary Hospital, Shanghai, China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yayi He

Professor

Shanghai Pulmonary Hospital, Shanghai, China

研究点 (1)

Loading locations...

相似试验